| Title |
Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status
|
|---|---|
| Published in |
PharmacoEconomics, November 2014
|
| DOI | 10.1007/s40273-014-0230-2 |
| Pubmed ID | |
| Authors |
John Cawley, Chad Meyerhoefer, Adam Biener, Mette Hammer, Neil Wintfeld |
| Abstract |
The prevalence of obesity has more than doubled in the USA in the past 30 years. Obesity is a significant risk factor for diabetes, cardiovascular disease, and other clinically significant co-morbidities. This paper estimates the medical care cost savings that can be achieved from a given amount of weight loss by people with different starting values of body mass index (BMI), for those with and without diabetes. This information is an important input into analyses of the cost effectiveness of obesity treatments and prevention programs. |
X Demographics
The data shown below were collected from the profiles of 26 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 15 | 58% |
| Australia | 1 | 4% |
| Finland | 1 | 4% |
| Sweden | 1 | 4% |
| Turkey | 1 | 4% |
| United Kingdom | 1 | 4% |
| Unknown | 6 | 23% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 62% |
| Scientists | 8 | 31% |
| Practitioners (doctors, other healthcare professionals) | 2 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 136 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Portugal | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 133 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 23 | 17% |
| Student > Master | 23 | 17% |
| Student > Bachelor | 16 | 12% |
| Researcher | 16 | 12% |
| Other | 9 | 7% |
| Other | 20 | 15% |
| Unknown | 29 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 18% |
| Nursing and Health Professions | 13 | 10% |
| Economics, Econometrics and Finance | 11 | 8% |
| Agricultural and Biological Sciences | 10 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 6% |
| Other | 36 | 26% |
| Unknown | 33 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 64. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 May 2018.
All research outputs
#603,122
of 23,936,280 outputs
Outputs from PharmacoEconomics
#14
of 1,929 outputs
Outputs of similar age
#6,891
of 265,894 outputs
Outputs of similar age from PharmacoEconomics
#3
of 28 outputs
Altmetric has tracked 23,936,280 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,929 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,894 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.